Cerus Corporation $CERS Shares Purchased by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC has increased its holdings in Cerus Corporation by 112.5%, now owning 1,898,621 shares valued at approximately $2.6 million.
• Cerus reported a loss of ($0.03) EPS in its latest quarterly earnings, missing the consensus estimate, despite revenue of $60.10 million exceeding expectations.
• As of the latest data, institutional investors and hedge funds collectively own 78.37% of Cerus Corporation's stock.

Acadian Asset Management LLC raised its position in shares of Cerus Corporation (NASDAQ:CERS - Free Report) by 112.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,898,621 shares of the biotechnology company's stock after acquiring an additional 1,005,079 shares during the period. Acadian Asset Management LLC owned approximately 0.99% of Cerus worth $2,637,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus in the first quarter worth $32,000. Millennium Management LLC lifted its holdings in shares of Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock worth $4,479,000 after purchasing an additional 344,395 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock worth $1,986,000 after purchasing an additional 1,064,133 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Cerus by 152.4% during the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company's stock worth $145,000 after purchasing an additional 62,854 shares during the period. Finally, Ieq Capital LLC raised its position in Cerus by 7.0% during the first quarter. Ieq Capital LLC now owns 2,320,796 shares of the biotechnology company's stock valued at $3,226,000 after acquiring an additional 151,309 shares in the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus Stock Performance

CERS stock traded up $0.16 during trading on Friday, hitting $1.46. 6,017,899 shares of the company traded hands, compared to its average volume of 1,079,960. The company has a market cap of $279.88 million, a PE ratio of -14.60 and a beta of 1.63. Cerus Corporation has a 1 year low of $1.12 and a 1 year high of $2.24. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.35. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35.

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The business had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. On average, equities analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.